RPAP3 enhances cytotoxicity of doxorubicin by impairing NF-kappa B pathway

Kana Shimada, Makio Saeki, Hiroshi Egusa, Sho Fukuyasu, Yoshiaki Yura, Kazuhiro Iwai, Yoshinori Kamisaki

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Activation of anti-apoptotic gene transcription by NF-κB (nuclear factor-kappa B) has been reported to be linked with a resistance of cancer cells against chemotherapy. NEMO (NF-κB essential modulator) interacts with a number of proteins and modulates the activity of NF-κB pathway. In this study, we revealed that RPAP3 (RNA polymerase II-associated protein 3) possesses an activity to bind with NEMO and to inhibit the ubiquitination of NEMO and that RPAP3 enhances doxorubicin-induced cell death in breast cancer cell line T-47D through the marked impairment of NF-κB pathway. These results indicate that RPAP3 may be a novel modulator of NF-κB pathway in apoptosis induced by anti-cancer chemotherapeutic agents.

Original languageEnglish
Pages (from-to)910-914
Number of pages5
JournalBiochemical and Biophysical Research Communications
Issue number4
Publication statusPublished - 2011 Jan 28


  • Monad
  • PIH1D1
  • R2TP
  • Reptin
  • RPAP3
  • WDR92


Dive into the research topics of 'RPAP3 enhances cytotoxicity of doxorubicin by impairing NF-kappa B pathway'. Together they form a unique fingerprint.

Cite this